Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vidaza

Celgene plans real-world study using Apple’s ResearchKit

Will develop an iPhone app to assess burden of chronic anaemia

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

- PMLiVE

PMEA 2016 finalists announced

AbbVie, Bayer, Celgene and Novartis are up for the prestigious Company of the Year

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up

Celgene building

Celgene bolsters blood cancer portfolio with $600m EngMab buy

Consolidates position as top company in current multiple myeloma market

- PMLiVE

Celgene disappointed as Revlimid fails lymphoma trial

Study shows improvement in progression-free survival but no overall survival rate benefit

Celgene building

Jounce bags $225m upfront in Celgene immuno-oncology deal

Five pipeline candidate agreement worth up to $2.5bn should Celgene claim the rights

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

Celgene building

NICE rejects Celgene’s Vidaza for leukaemia

Final draft guidance cites ‘high degree of uncertainty’ over clinical efficacy

Celgene building

Celgene takes aim at cancer innovation with new US research consortium

Academic tie-up aims to develop new therapeutics and diagnostics

Celgene building

Celgene forms real-time, real-world trial partnership

Will collaborate with TriNetX, using its electronic medical records network

- PMLiVE

Celgene launches ‘edu-tainment’ psoriasis awareness initiative

Millefeuille film seeks to highlight everyday burden of the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links